Investigating the role of pancreatic hormones in Congenital Hyperinsulinism

Great Ormond Street NHS Hospital for Children

NHS Foundation Trust

Güemes M^{1,2}, Gilbert C², Morgan K², Rahman SA¹, Hussain K^{1,2}

1. GGM Programme, GEHD section, Institute of Child Health, University College London 2. Endocrinology Department, Great Ormond Street Hospital for Children, London



INTRODUCTION

Congenital hyperinsulinism (CHI) is a cause of persistent hypoglycaemia. Children with CHI have dysregulated insulin secretion and very often present feeding issues. Amylin and pancreatic polypeptide (PP) are produced in the pancreas and have been reported to have anorectic action on feeding and therefore it is possible that they could also be dysregulated in CHI. We investigated the response of pancreatic hormones (insulin, C-peptide, amylin and PP) after a fast in children diagnosed with CHI due to different underlying mechanisms.

MATERIALS AND METHODS

Plasma pancreatic hormones were collected in 12 children with CHI at GOSH. Once consent was obtained from parents, the samples were collected at normoglycaemia and at hypoglycaemia (end of fast). Analysis of the hormones was performed in multiplexing manner (Luminex Multiplex assay) on 0.025ml of plasma^{1,2}. The multiplex plate containing the beads, antibodies and plasma is run on a Luminex machine where the median fluorescent intensity data is analysed using a weighed 5-parameter logistic or spline-fitting method for calculating analyte concentrations.


RESULTS


Patients' characteristics:


| | Patient ID | Gender | Age | Feeding Route | CHI treatment | Medications | Responsive to this Treatment | Pancreatectomy | Genetics for CHI | Histology/ PET scan |
|-----------------|---------------|--------|------|------------------|------------------|--|------------------------------|----------------|--|------------------------|
| + | 1 | Male | 1y6m | Oral | 20% Dex | No | No | No | Negative | Diffuse |
| + | 2 | Male | 14d | Oral | 25% Dex | No | No | No | Maternal heterozygous ABCC8 | Diffuse |
| + | 3 | Female | 3m | Oral | 20% Dex | Octreotide, Domperidone, Lansoprazole | Yes | Lesionectomy | Paternal heterozygous ABCC8 | Focal |
| - 17 | 4 | Male | 4y1m | Oral | 10% Dex | Tompiramate, Levetiracetam, Clonazepam, Azithromycin | No | Lesionectomy | Negative | Focal |
| A. | 5 | Female | 9m | Oral | 15% Dex | No | No | Lesionectomy | Paternal <i>KCNJ11</i> non stop mutation | Focal |
| 1 | 6 | Male | 11d | Oral | Dex | No | Yes | No | Negative | ? |
| + | 7 | Female | 2m | Continuou s | 40% Dex | Glucagon | No | No | Negative | Diffuse |
| | 8 | Female | 1m7d | Oral | 30% Dex | No | No | No | Negative | Diffuse |
| | 9 | Male | 5m | Oral | 20% Dex | No | No | Subtotal | Homozygous ABCC8 | Diffuse |
| + | 10 | Female | 9m | NG | Dex | No | No | No | Negative | ? |
| + | 11 | Female | 2m | Oral | Dex | No | No | No | Negative | ? |
| + | 12 | Female | 13y | Oral | No | No days, mimonths, Dov. Dovtroso | Not applicable | No | Negative | CHI/ ?Insulinoma |


Hormone analysis:

| | <u>NORMOGLYCAEMIA</u> | | | | | | | | |
|-----------------------|-----------------------|---------------|--------------|---------|--------------|--|--|--|--|
| | Amylin Total | C- Peptide | Glucagon | Insulin | PP | | | | |
| Average | 34.6 | 1546.8 | 97.3 | 909.2 | 83.8 | | | | |
| SEM | 7.3 | 292.5 | 72.0 | 127.5 | 30.7 | | | | |
| SD | 21.8 | 1013.1 | 238.8 | 441.5 | 106.5 | | | | |
| Mean +2SD | 78.3 | 3573.0 | 574.9 | 1792.2 | 296.7 | | | | |
| Mean - 2SD | -9.1 | -479.4 | -380.2 | 26.2 | -129.1 | | | | |
| t test CHI N vs. H | 0.014 | 0.005 | <u>0.214</u> | 0.004 | <u>0.654</u> | | | | |
| n | 9 | 12 | 11 | 12 | 12 | | | | |
| | <u>HYPOGLYCAEMIA</u> | | | | | | | | |
| | Amylin Total | C- Peptide | Glucagon | Insulin | PP | | | | |
| Average | 21.2 | 805.5 | 103.3 | 502.8 | 85.7 | | | | |
| SEM | 3.5 | 105.5 | 75.1 | 88.5 | 33.1 | | | | |
| SD | 9.3 | 365.6 | 260.0 | 306.4 | 114.6 | | | | |
| Mean +2SD | 39.8 | 1536.8 | 623.3 | 1115.7 | 314.9 | | | | |
| Mean - 2SD | 2.5 | 74.3 | -416.7 | -110.1 | -143.5 | | | | |
| n | 7 | 12 | 12 | 12 | 12 | | | | |









CONCLUSIONS

- This assay has now proven to be useful in determining pancreatic hormones in children
- This study confirms that glucagon's response to hypoglycaemia is impaired in children with CHI³
- This is the first study to look at amylin concentrations in CHI
- Amylin decreases during hypoglycaemia so as to avoid it's anorectic effect, but interestingly PP's remain stable concentrations despite hypoglycaemia, possibly indicating a paracrine effect that needs to be confirmed at the pancreatic level

REFERENCES

1.- Hum M et al. Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol Res. 2011;60(4):647-58. Epub 2011 May 16.

Hypoglycaemia

- 2.- Papastamataki M et al. Incretins, amylin and other gut-brain axis hormones in children with coeliac disease. Eur J Clin Invest. 2014 Jan;44(1):74-82
- 3.- Hussain K et al.. Serum glucagon counterregulatory hormonal response to hypoglycemia is blunted in congenital hyperinsulinism. Diabetes 2005;54:2946–2951

Misc 3

Normoglycaemia

Poster presented at:





